The Microscopy Shared Resource (MSR) is a centrally-located resource with cutting-edge instruments and highly trained experts to provide outstanding support for OSUCCC scientists for confocal, light, scanning electron and transmission electron microscopy, the MSR has two electron microscopes and four confocals all purchased since 2005 through federal grants and outstanding institutional support. These instruments include two single photon Olympus FVI 000 confocal microscopes each with four lasers and high N.A. objectives specifically for fixed cells and tissue, an FEI Tecnai BioTwin transmission electron microscope, and an Olympus FVI 000 multiphoton confocal instrument with a MaiTai DeepSee laser to probe deep into tumors in both live animals and fixed tissue. The MSR is led by Dr. Richard Burry, an established and well funded scientist with over 30 years of extensive expertise in microscopy, who along with an experienced and highly-trained staff, provides OSUCCC investigators vital consultation in experimental design and image analysis. Usage and productivity from the MSR is enhanced by well-organized training courses and individual training offered by staff members. The MSR is extensively used across OSUCCC scientific programs providing service to >30 OSUCCC member labs to generate the images for high quality cancer relevant publications and grants. The MSR is centrally located on the second floor of the Biomedical Research Tower (BRT) close to the labs of the OSUCCC members. Based on the expanding capabilities of the MSR and increases in number of grant applications from OSUCCC members, the OSUCCC usage is estimated to increase dramatically over the next five years based on strategic recruitment goals and expanded demand for high-end microscopy in cancer research. The MSR is supported by outstanding institutional resources by leveraging extensive partnerships with OSU Colleges, the OSU Office of Research, grants from the State of Ohio and the OSUCCC. The MSR is a new OSUCCC shared resource, previously with a strong user base as an OSU core facility, and thus fulfills NIH goals to consolidate core facilities for maximal efficiency and utilization by NIH funded investigators. Collectively the MSR is a critical shared resource for OSUCCC investigators seeking to identify specific cells and proteins in normal tissue and in tumors to enhance our understanding of fundamental processes of cancer in developing therapeutic strategies.

Public Health Relevance

The Microscopy Shared Resource (MSR) provides timely and high quality service to support OSUCCC investigators in a convenient, central location. Instrumentation and expert technical advice and training support a variety of sophisticated approaches in cancer research including: detection of viruses with transmission electron microscopy, examination of nanostructures for drug delivery with cryo-transmission electron microscopy, live cell imaging of cells in response to different treatments, multiple beam live cell confocal, reconstruction of pre-clinical breast tumor models using multiphoton microscopes, and following movement of immune cells in tumors of living animals with multiphoton microscopy. The MSR provides a vital shared resource for cancer investigators to translate cancer biology to new treatments against cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016058-38
Application #
8601821
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-12-01
Budget End
2014-11-30
Support Year
38
Fiscal Year
2014
Total Cost
$70,770
Indirect Cost
$24,363
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Slayton, William B; Schultz, Kirk R; Kairalla, John A et al. (2018) Dasatinib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0622. J Clin Oncol 36:2306-2314
Bassett, Emily A; Palanichamy, Kamalakannan; Pearson, Mitchell et al. (2018) Calpastatin phosphorylation regulates radiation-induced calpain activity in glioblastoma. Oncotarget 9:14597-14607
Trn?ný, Marek; Verhoef, Gregor; Dyer, Martin Js et al. (2018) A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy. Haematologica 103:1351-1358
Bishop, Erin A; Java, James J; Moore, Kathleen N et al. (2018) Surgical outcomes among elderly women with endometrial cancer treated by laparoscopic hysterectomy: a NRG/Gynecologic Oncology Group study. Am J Obstet Gynecol 218:109.e1-109.e11
Kim, Miriam Y; Yu, Kyung-Rok; Kenderian, Saad S et al. (2018) Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia. Cell 173:1439-1453.e19
Malpeli, Giorgio; Barbi, Stefano; Tosadori, Gabriele et al. (2018) MYC-related microRNAs signatures in non-Hodgkin B-cell lymphomas and their relationships with core cellular pathways. Oncotarget 9:29753-29771
Niemas-Teshiba, Risa; Matsuno, Ryosuke; Wang, Larry L et al. (2018) MYC-family protein overexpression and prominent nucleolar formation represent prognostic indicators and potential therapeutic targets for aggressive high-MKI neuroblastomas: a report from the children's oncology group. Oncotarget 9:6416-6432
Sharpnack, Michael F; Chen, Bin; Aran, Dvir et al. (2018) Global Transcriptome Analysis of RNA Abundance Regulation by ADAR in Lung Adenocarcinoma. EBioMedicine 27:167-175
Tanaka, Ichidai; Sato, Mitsuo; Kato, Toshio et al. (2018) eIF2?, a subunit of translation-initiation factor EIF2, is a potential therapeutic target for non-small cell lung cancer. Cancer Sci 109:1843-1852
Bell, Erica H; Zhang, Peixin; Fisher, Barbara J et al. (2018) Association of MGMT Promoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and Temozolomide: An Analysis From the NRG Oncology/RTOG 0424 Trial. JAMA Oncol 4:1405-1409

Showing the most recent 10 out of 2602 publications